|
Sep 19
|
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
|
|
Sep 18
|
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
|
|
Sep 18
|
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
|
|
Sep 17
|
Company News for Sep 17, 2024
|
|
Sep 17
|
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
|
|
Sep 16
|
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
|
|
Sep 16
|
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data
|
|
Sep 16
|
Nuvalent Announces Public Offering of Common Stock
|
|
Sep 14
|
Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks
|
|
Sep 14
|
Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
|
|
Sep 14
|
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
|
|
Sep 13
|
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
|
|
May 9
|
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
|
|
May 8
|
Why Earnings Season Could Be Great for Nuvalent (NUVL)
|
|
Apr 8
|
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
|
|
Apr 5
|
Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)
|
|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
|
Mar 29
|
Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)
|
|
Mar 25
|
Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)
|
|
Mar 22
|
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
|